Mariana Moualem, F.N.P.; Decision and Order
Mariana Moualem, F.N.P., has been sanctioned by the DEA, likely involving revocation or suspension of her DEA registration. This signals heightened scrutiny on nurse practitioners prescribing controlled substances, potentially affecting pharmacies that fill prescriptions from such practitioners.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Independent pharmacies, retail chains, and long-term-care pharmacies that fill controlled substance prescriptions from nurse practitioners (NPs) or other mid-level practitioners. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Within 30 days, but ongoing monitoring recommended.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
DEA has issued a Decision and Order against Mariana Moualem, F.N.P., indicating enforcement action (e.g., revocation of DEA registration) for non-compliance with controlled substance regulations. This may lead to increased audits or stricter verification requirements for prescriptions from NPs.
Who it affects
Independent pharmacies, retail chains, and long-term-care pharmacies that fill controlled substance prescriptions from nurse practitioners (NPs) or other mid-level practitioners.
What you must do
Review and verify the DEA registration status of all nurse practitioners and mid-level practitioners you work with. Ensure your pharmacy has processes to check for DEA actions against prescribers.
Deadline
Within 30 days, but ongoing monitoring recommended.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order